검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fludarabine Phosphate (Fludarabine Phosphate) CTI BioPharma·B-cell Acute Lymphoblastic Leukemi… ORR 59%·t½ 6 h |
|---|---|
Overview Program | Fludarabine Phosphate |
Overview Company | CTI BioPharma |
Overview Modality | ANTIBODY |
Overview Target | B-cell Acute Lymphoblastic Leukemia |
Overview Indication | Leukemia; Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeted metabolomic profiling of plasma samples was conducted to identify significantly altered metabolites and enriched metabolic pathway |
MoA Biomarker | biomarker study in HLA-haploidentical hematopoietic cell transplant recipients |
PK/PD Half-life | 6 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Dog, Mouse, Rat, Rabbit, Hamster, Human |
Toxicology Animal (cat.) | Mouse, Rat, Dog |
Toxicology Major finding | pneumonitis and respiratory failure |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT00602459 |
Clinical Data Tier / Score | A · 63 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fludarabine Phosphate (Fludarabine Phosphate) CTI BioPharma·B-cell Acute Lymphoblastic Leukemi… ORR 59%·t½ 6 h |
|---|---|
Overview Program | Fludarabine Phosphate |
Overview Company | CTI BioPharma |
Overview Modality | ANTIBODY |
Overview Target | B-cell Acute Lymphoblastic Leukemia |
Overview Indication | Leukemia; Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeted metabolomic profiling of plasma samples was conducted to identify significantly altered metabolites and enriched metabolic pathway |
MoA Biomarker | biomarker study in HLA-haploidentical hematopoietic cell transplant recipients |
PK/PD Half-life | 6 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Dog, Mouse, Rat, Rabbit, Hamster, Human |
Toxicology Animal (cat.) | Mouse, Rat, Dog |
Toxicology Major finding | pneumonitis and respiratory failure |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT00602459 |
Clinical Data Tier / Score | A · 63 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교